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Chronic allograft nephropathy: An update. Chronic allograft pathophysiology are highlighted. The final section of this
nephropathy is the most prevalent cause of renal transplant overview touches on the lack of effective treatment strat-
failure in the first post-transplant decade, but its pathogenesis egies to prevent or treat chronic allograft nephropathyhas remained elusive. Clinically, it is characterized by a slow
clinically, despite the successes obtained with some treat-but variable loss of function, often in combination with protein-
ment modalities in animal models.uria and hypertension. The histopathology is also not specific,
but transplant glomerulopathy and multilayering of the peritu-
bular capillaries are highly characteristic. Several risk factors
CLINICAL AND HISTOPATHOLOGICALhave been identified, such as advanced donor age, delayed graft
function, repeated acute rejection episodes, vascular rejection FEATURES OF CHRONIC
episodes, and rejections that occur late after transplantation. ALLOGRAFT NEPHROPATHY
A common feature of chronic allograft nephropathy is that
Chronic allograft nephropathy is characterized by ait develops in grafts that have undergone previous damage,
although the mechanism(s) responsible for the progressive fi- relatively slow but variable rate of decline in renal func-
brosis and tissue remodeling has not yet been defined. Hypoth- tion after the initial three post-transplant months, often
eses to explain chronic allograft nephropathy include the im- in combination with proteinuria and aggravation or de
munolymphatic theory, the cytokine excess theory, the loss of
novo appearance of hypertension [6]. Linear regressionsupporting architecture theory, and the premature senescence
analysis of the reciprocal of the serum creatinine concen-theory. The most effective option to prevent chronic allograft
nephropathy is to avoid graft injury from both immune and tration over time shows progressive of loss of function
nonimmune mechanisms. in more than 80% of patients with histologically proven
chronic allograft nephropathy [7, 8]. Twenty to 28% of
patients with chronic allograft nephropathy have more
Interest in late renal transplant loss has increased sub- than 0.5 g proteinuria per 24 hours compared with 6 to
stantially as it has become evident that improvements 8% of patients who do not have this condition [9]. The
in the one-year graft survival rate have not resulted in diagnostic value of post-transplant hypertension is very
decreased graft attrition after the first year [1]. Up to limited because of its high prevalence [10]. None of these
40% of grafts develop progressive dysfunction after the clinical manifestations are specific, and other causes of
initial few post-transplant months and ultimately fail graft dysfunction such as acute rejection, drug toxicity,
within a decade, despite the use of immunosuppressive or glomerulonephritis need to be excluded to make the
drugs in doses sufficient to prevent acute rejection [2]. diagnosis of chronic allograft nephropathy.
This form of graft failure has been called chronic rejec- The histopathology of chronic allograft nephropathy
tion [3], however, immune and nonimmune factors are is also not specific and consists of atherosclerosis, glomer-
involved in its pathogenesis [4, 5], and the more neutral ular lesions and glomerular sclerosis, multilayering of the
terms chronic allograft nephropathy or chronic allograft peritubular capillaries, interstitial fibrosis, and tubular
dysfunction have been coined. In this overview, the histo- atrophy. Graft atherosclerosis consists of mostly concen-
pathology and risk factors of chronic allograft nephropa- tric intimal thickening that affects large parts of arteries
thy are reviewed, and existing hypotheses regarding its and arterioles, often accompanied by a moderate degree
of infiltration of the vessel wall with macrophages, lym-
phocytes, and, to a much lesser extent, foam cells. The
Key words: renal transplantation, transplant failure, immuno-lym-
intimal thickening is thought to result from the migrationphatic theory, cytokines, graft injury.
of (myo)fibroblasts from the media into the intima, fol-
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undergo dilation unless there is concomitant adventitial new antirejection agents and to guide therapy [24–26].
Although the Banff scheme has focused mainly on thefibrosis resulting in shrinking of the lumen [11].
The glomerular lesions of chronic transplant nephrop- classification of acute rejection based on routine light
microscopy readings, the more recent versions of theathy are variable and include wrinkling and collapse of
the glomerular tuft, glomerular hypertrophy [12], mesan- scheme deal in more detail with chronic allograft ne-
phropathy. Recognizing that tubulointerstitial changesgial matrix expansion, and focal glomerulosclerosis [13].
In 1964, Hamburger, Crosnier, and Dormont described are most accurately sampled and appear to have prog-
nostic significance [27], the grading of severity of chronictransplant glomerulopathy [14] as a lesion characterized
by enlargement of the glomeruli, with swelling of the rejection focused initially on interstitial fibrosis and tubu-
lar atrophy, but the most recent version includes gradingendothelial and mesangial cells, mesangiolysis, infiltra-
tion of the glomeruli with mononuclear cells, mesangial of chronic glomerular and vascular changes [26].
matrix expansion, and widening of the subendothelial
zone with interposition of mesangial cells and matrix
RISK FACTORS
[15].
An analysis of risk factors of chronic allograft ne-Immunofluorescent studies of grafts with chronic allo-
phropathy has mostly focused on postdonation events.graft nephropathy show, in most cases, a nondiagnostic
However, donor age explains approximately 30% of thepattern of immunoglobulin deposition, although some
variance in graft outcome beyond one year [28]. Ancases show linear IgG deposits along the glomerular
analysis by Terasaki et al using the UNOS Scientificbasement membrane or granular deposits of IgG or IgA
Renal Transplant Registry data demonstrated a strongin peripheral capillary loops [16]. On electron micro-
effect of donor age on long-term outcome and graft half-scopic examination, circumferential multilamellation of
life [29]. The authors attributed this effect to a relativethe peritubular capillary basement membranes is found
deficiency in the number of nephrons vis-a-vis the recipi-in 80% of grafts with chronic allograft nephropathy [17].
ent’s metabolic demands.Although this lesion is not specific, more than seven
Transplants with prolonged ischemic exposure and de-layers of basement membranes seem specific and are
layed graft function also experience inferior long-termfound in 38% of chronic allograft nephropathy speci-
outcome [30], as do grafts that have been exposed tomens [18].
acute rejection episodes [31, 32]. Repeated, severe, andImmunohistochemical studies have shown deposition
prolonged acute rejection episodes [32], as well as rejec-of extracellular matrix proteins such as tenascin and the
tion episodes that occur months or years after trans-extradomain A (EDA) isoform of cellular fibronectin in
plantation, are at a high risk of evolving into chronicthe glomeruli, the vessel wall, and the interstitium [19,
allograft nephropathy [9].20]. These molecules are involved in tissue remodeling
Approximately 50% of biopsies taken during an acuteand are found in a variety of conditions such as acute
rejection episode show endarteritis, a histopathologicalrejection, lupus nephritis, and diabetic nephropathy [21].
characteristic that makes the rejection episode less re-A comparison of chronic allograft nephropathy and na-
sponsive to steroids. Sticking of mononuclear cells totive kidney diseases has shown that both forms of renal
endothelial cells also correlates to steroid resistance,scarring exhibit similar extracellular matrix composition
whereas rejection with fibrinoid necrosis does not re-consisting of the normal basement membrane compo-
spond to either steroids or antibodies. Therefore, acutenents collagen type IV, laminin, and heparan sulfate,
vascular rejection and endarteritis are highly statisticallyas well as decorin and collagen type III, whereas the
adverse prognostic features compared with tubulointer-glomerular matrix accumulation is entirely due to in-
stitial rejection [33, 34]. Other biopsy features that corre-creased deposition of normal glomerular extracellular
late with chronic allograft nephropathy are tissue infil-matrix components [22]. Thus, there seems no funda-
tration with large numbers of monocytes or macrophagesmental difference in the composition of the extracellular
and large numbers of class II-positive tubular and inter-matrix in kidneys with native glomerular disease and
stitial cells [35].chronic allograft nephropathy. However, a recent study
Graft biopsies from patients with elevated cholesterolcompared kidneys with chronic allograft nephropathy
levels more often display more severe chronic damageand chronic cyclosporine (CsA) toxicity and found new
than biopsies from patients with lower cholesterol levels,expression of collagen type IV and laminin in the former
although not all studies have found this association [36,condition and accumulation of collagens I and III in
37]. In multivariate analyses, hypertriglyceridemia is anchronic CsA nephrotoxicity [23].
independent risk factor of late graft loss [9]. RecipientSince 1991, there have been four international meet-
hypertension also portends a poorer outcome with aings in Banff, Canada, to standardize renal transplant
faster decline in function and a greater likelihood ofpathology interpretations and reporting to establish ob-
jective and reproducible end points for clinical trials of return to dialysis compared with patients with a normal
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blood pressure [38]. Finally, impaired graft function at phropathy. Similar arguments can be made for the cal-
6 or 12 months is also a risk factor for late graft loss [39]. cineurin inhibitor tacrolimus or FK-506; both CsA and
Cytomegalovirus (CMV) infections enhance chronic vas- tacrolimus can cause functional and histological renal
cular rejection in cardiac transplant patients and experi- impairments that are difficult to differentiate from
mental animals; however, such a correlation has not been chronic allograft nephropathy [44, 45]. Glucocorticoids
found in renal transplant patients [9], and studies of also accelerate the development of proteinuria and glo-
transplants with chronic allograft nephropathy have merulosclerosis in renal ablation models [46]. Further-
failed to show CMV mRNA or protein in such grafts. more, CsA, corticosteroids, and tacrolimus aggravate hy-
A multivariate analysis in our center of kidney trans- pertension, whereas the former two drugs also have
plants, which failed after the initial six months, identified detrimental effects on lipid metabolism. The lack of ran-
several independent risk factors of chronic allograft domized trials with robust follow-up information makes
nephropathy, including donor age, acute rejection his- it difficult to assess the impact of various immunosup-
tory, graft function at six months, smoking, and pro- pressive drug regimens on long-term outcome, although
teinuria. In addition to these factors, it was found that some information is available from registry data and
sharing of broadly cross-reactive class I antigens (so- mostly underpowered single-center studies. It is impor-
called CREGs) confers protection against late graft fail- tant to note that registry data on immunosuppressive
ure, whereas matching for human lymphocyte antigens drug therapies should be regarded with caution, as they
(HLAs) had no effect (abstract; Sijpkens et al, J Am Soc are not derived from randomized trials and often reflect
Nephrol 9:699A, 1998). a treatment bias.
Another recent study separately analyzed the risk fac-
tors of tubulointerstitial fibrosis or transplant glomerulo- Corticosteroids
pathy and nephrotic proteinuria in patients with chronic In the Collaborative Transplant Study database, the
allograft nephropathy [40]. Significantly more black re- five-year graft survival and projected graft half-life rates
cipients, female donors, and preceding steroid sensitive- were significantly better in patients who had been
rejection episodes were found in the transplant glomeru- switched from CsA, steroids, and azathioprine to steroid-
lopathy group, whereas the donor/recipient surface area free maintenance immunosuppression with CsA, with or
ratio, a surrogate marker for donor/recipient size match- without azathioprine [47, 48], suggesting that the detri-
ing, was significantly lower compared with the patients mental effect of corticosteroids exceeds their potential
with interstitial fibrosis, suggesting that glomerular hy- benefit on long-term graft outcome. However, only 10%
perfiltration and hypertension play a role in transplant of patients reported were treated with steroid-free main-
glomerulopathy [40]. On the other hand, the degree of tenance regimens, and it is likely that the group in whom
HLA mismatching was higher in patients with tubuloin- steroids were withdrawn were mostly low-risk patients.
terstitial fibrosis but was not different between the trans- A Canadian multicenter steroid-withdrawal study of pa-
plant glomerulopathy group and control cases, support- tients treated with triple therapy found a better five-
ing the supposition that immune mechanisms play a year graft survival (85%) in patients who continued on
dominant role in the tubulointerstitial fibrosis of chronic
prednisone (0.3 mg/kg on alternate days) compared with
allograft nephropathy.
73% in patients who were treated with an “ultra-low”
dose of prednisone (2 to 3 mg on alternate days) three
IMMUNOSUPPRESSION AND LONG-TERM months after transplantation. The graft survival curves
GRAFT OUTCOME of the two groups were dissociated 1.5 to 2 years after
study enrollment and suggest a beneficial effect of ste-Prior to 1982, standard immunosuppression consisted
roids on long-term prognosis. When risk factors con-of the combination of corticosteroids and azathioprine,
founding graft survival were included in the analysis,complemented in some centers with the prophylactic use
no significant influence of assigned treatment on graftof antilymphocyte antisera in the first few post-transplant
survival was found [49], but the direction was still inweeks. The addition of the calcineurin inhibitor CsA in
favor of maintenance of corticosteroids. In a single-cen-the early 1980s resulted in a decreased incidence of acute
ter study from Leiden, prednisone was withdrawn onerejection episodes and an improved one-year graft sur-
year after transplantation, which resulted in an increasevival rate, but it did not seem to affect the rate of graft
in the incidence of acute rejection episodes, a largerattrition after the first post-transplant year [41]. This
but nonsignificant loss of renal function, and a higherraises the question as to whether its immunosuppressive
proportion of patients with proteinuria in the prednisoneefficacy is off-set by its nephrotoxic side-effects [42],
withdrawal group [50]. Although there was no differencewhether inadequate drug doses have been prescribed
in graft survival, it remains to be seen whether the deteri-because of concerns of nephrotoxicity [31, 43], or
whether the drug has no effect on chronic allograft ne- oration of function is an early sign of chronic allograft
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nephropathy, as expected from an increased incidence was not detectable any more after two years of follow-
up, except in a subgroup of sensitized patients [60]. CsAin late acute rejection episodes [51].
Several recent reports have shown that steroids can be was the baseline immunosuppressant in all these trials,
and the impact of ’induction“ therapy in tacrolimus andwithdrawn safely in patients treated with mycophenolate
mofetil (MMF) [52], MMF and tacrolimus (abstract; MMF-based maintenance therapies has not been exam-
ined yet. A comparison of the results of the U.S. and theGrewal et al, Transplantation 65:S167, 1998) or with ra-
pamycin (abstract; Kahan et al, Transplantation 65:S167, Tricontinental Mycophenolate Mofetil Renal Transplant
Studies [61, 62] may provide some insight in the efficacy1998), but no long-term data are available to assess its
impact on chronic allograft nephropathy. of antibody induction in conjunction with MMF. In the
U.S. study, MMF in combination with CsA, corticoste-
Azathioprine roids, and antithymocyte g-globulin gave a three-year
graft survival of 86.0% compared with 83.1% in the Tri-Data from the Collaborative Transplant Study registry
showed no difference in the estimated half-life of kidney continental Study in which patients received MMF, CsA,
and corticosteroids without antibody induction.transplants in patients treated with CsA plus corticoste-
roids only compared with CsA, steroids, and azathio-
Cyclosporineprine (17.4 vs. 17.6 years, respectively) [48], suggesting
that azathioprine does not improve long-term outcome. The introduction of CsA has improved the short-term
results of kidney transplantation significantly, but it isA meta-analysis of five trials comparing these two regi-
mens also failed to show a significant difference in patient not clear whether this results in a decreased incidence
of chronic allograft nephropathy. In the UCLA/UNOSor graft survival, although there was a trend toward bet-
ter graft survival under triple therapy [53]. In a British database, the introduction of CsA in the 1980s has not
affected the graft half-lives [1], but other studies reportedtrial, no differences in graft survival were found in pa-
tients treated with either triple therapy, dual therapy some long-term benefit. The Eurotransplant registry
data showed a slightly longer half-life in CsA-treatedwith CsA and azathioprine, or monotherapy with CsA
only [54]. A recently published randomized study of pa- patients transplanted between 1981 and 1987 compared
with patients transplanted between 1981 and 1984 whotients treated with dual therapy consisting of 10 mg/kg/
day of CsA plus prednisone or triple therapy consisting did not receive CsA [63], and similar data have been
published from individual centers [64].of 6 mg/kg/day of CsA plus azathioprine and prednisone
found a similar incidence of chronic graft dysfunction in Concerns regarding CsA’s nephrotoxicity and adverse
effect profile instigated several trials of CsA withdrawalboth groups (17% in the double-therapy group compared
with 15.5% in the triple-therapy group), but the four- at various time intervals after transplantation. However,
analysis of more than 12,000 patients reported to theyear graft survival was better in the triple-therapy group
(83 compared with 71% in the double-therapy group, Collaborative Transplant Study showed the worst five-
year graft survival in patients who initially received CsA,P 5 0.089) [55].
azathioprine, and corticosteroids and who were switched
Antilymphocyte antibody prophylaxis in the first year to corticosteroids and azathioprine,
whereas the best results were obtained in patients whoMany investigators, especially in North America, have
explored the benefits of the prophylactic use of antibod- had remained on CsA plus azathioprine or CsA only
[47]. The half-lives were 10.5 years for grafts treated withies or antisera against lymphocytes in the immediate
post-transplant period, a regimen often referred to as steroids and azathioprine, 30.0 years for grafts treated
with CsA only, and 26.6 years for grafts treated withinduction therapy [reviewed in 56]. Although most co-
hort studies and all randomized controlled trials individ- CsA and azathioprine [48]. These observations and pro-
jections are at variance with the results of a meta-analysisually have failed to demonstrate a benefit, large registry
data show a graft survival benefit in patients who were concerning 10 randomized and 7 nonrandomized trials
of elective CsA discontinuation at some time point aftertreated with antilymphocyte preparations [57, 58].
Cecka, Gjertson, and Terasaki reported an 8.1% greater surgery. Although these trials showed a greater com-
bined rate of acute rejection among patients from whomone-year survival rate in the antibody-treated group [57].
Opelz found a 3.9 and 2% survival advantage at three the drug was withdrawn compared with patients who
continued to receive CsA, there were no differences inand five years, respectively [56, 58], but the incidence
of lymphoproliferative disease increased substantially in graft loss or mortality attributable to CsA withdrawal
after 26.6 6 7.5 months of follow-up [65].the antibody-treated group [56]. A recently published
meta-analysis of seven randomized controlled trials of A prospective CsA conversion study in our center
of 128 patients who were randomly assigned to eitherprophylactic antilymphocyte antibody treatments dem-
onstrated a 6% greater two-year graft survival rate in continuation of CsA or switching to azathioprine at three
months showed an eight-year patient survival of 75.3%the treated group [59]. This benefit waned with time and
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in patients who had remained on CsA and of 85.9% in tory response consisting of an influx of lymphocytes and
monocytes, proliferation of tissue fibroblasts, depositionthe azathioprine group (P 5 0.14); the graft survival
rates were 64.0 and 76.6%, respectively (P 5 0.38) [66]. of extracellular matrix material, scar formation, and ulti-
mately tissue restoration. Whereas ischemic damage andChronic allograft nephropathy was diagnosed in 12% of
CsA-treated patients and in 8% of azathioprine-treated acute rejection episodes resolve more or less completely
in most instances, irreversible fibrosis sometimes ensues.patients. The 13-year follow-up of this trial shows that
the uncensored half-life of patients who remained on The duration and extent of damage are intuitively impor-
tant determinants, but the exact molecular mechanismsCsA was 11.1 years versus 15.7 years in patients who
were converted to azathioprine (unpublished data). The involved remain far from clear. A myriad of mediators,
including proinflammatory cytokines, enzymes, anddifferences were not significant because the study was
not empowered to detect differences in long-term graft growth factors such as transforming growth factor-b
(TGF-b), platelet-derived growth factor, interleukin-1b,survival.
tumor necrosis factor-a, angiotensin II, and endothelin
Tacrolimus or FK 506 [73], seems involved in various stages of the inflamma-
tory and tissue restoration responses. These mediatorsIn a randomized open-label trial comparing tacrolimus
with CsA, a significant reduction in the incidence and are synthesized and secreted by both tissue-invading in-
flammatory cells and by activated graft parenchymalseverity of biopsy-proven acute rejection episodes was
found in the tacrolimus group, but the one-year patient cells. Interestingly, the amount of cytokines produced in
vitro by blood cells from different individuals in responseand graft survival results were similar [67]. It remains to
be seen whether there will be a difference in long-term to a standard stimulus varies several-fold, and these dif-
ferences correlate with independently segregating ge-outcome. In the UNOS kidney transplant registry, the
projected half-life of 544 transplants treated with tacroli- netic polymorphisms [74–76]. The importance of such
polymorphisms in disease pathogenesis is currently un-mus was 15.3 years compared with 8.5 years in more than
known.35,000 grafts treated with CsA [68]. Caution is warranted
In addition to alloantigen-driven chronic inflamma-because these data were not obtained from randomized
tion, the situation in kidney transplants with chronictrials, the tacrolimus data were scarce, and center-
allograft nephropathy becomes further complicated byrestricted and virtually all patients treated with CsA re-
the fact that reduction in renal mass results in an increaseceived the old formulary of gel capsules. However, using
in glomerular capillary blood flow and pressure [77],the same database updated with additional information,
increased glomerular permeability characteristics [78],it was confirmed that tacrolimus improves graft survival
glomerular hypertrophy [79], changes in renal metabo-and half-life [69].
lism [80, 81], and the emergence of lipoprotein disorders
Mycophenolate mofetil secondary to uremia and proteinuria [82]. It has been
proposed that glomerular hypertension causes increasedMycophenolate mofetil in conjunction with CsA de-
trafficking of macromolecules through the mesangiumcreases the incidence of acute rejection in the first six
and mesangial expansion, ultimately culminating in glo-months after transplantation by approximately 50%
merulosclerosis. Besides hemodynamics, when the glo-compared with placebo or azathioprine [70–72]. At three
merular permselective property is lost, increased glomer-years, both intent-to-treat and on-study analyses of graft
ular filtration of macromolecules results in the deliveryand patient survival showed a nonsignificant trend to-
of abnormal amounts of protein in the tubular filtrate.ward an advantage for MMF and renal function, and
These proteins are largely reabsorbed by the proximalurinary protein excretion rates were not different among
tubular cells and result in protein overload, cellular dam-the groups [62]. Thus, MMF does not seem to have an
age, and accumulation of proteins and lysosomal en-impact on long-term graft function and survival, but it
zymes into the interstitial space, which, in turn, contrib-should be noted that the study was not designed to show
utes to renal scarring [83, 84].differences in long-term outcome. Taken together, there
Micropuncture studies in rats have indeed shown glo-is currently not any particular drug regimen that is supe-
merular hypertension in kidney grafts with chronic allo-rior over any other regimen to prevent late graft loss
graft nephropathy [85–87], whereas lowering of the pres-and chronic allograft nephropathy, but it remains to be
sure results in improved graft survival, decreasedseen whether more recently introduced drugs like rapa-
proteinuria, and preservation of graft structure [88, 89].mycin will improve long-term outcome.
However, it is unlikely that glomerular hypertension is
sufficient to explain chronic allograft nephropathy, as
TISSUE RESPONSE TO INJURY glomerular hypertension in syngeneic grafts does not
Renal injury results in functional impairment and result in chronic allograft nephropathy [85]. It would
rather seem that glomerular hypertension is a permissivestructural damage, followed by a stereotypic inflamma-
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or progression factor in the pathogenesis of chronic allo- parenchyma. Studies done long ago have shown that the
lymphatics from a renal transplant eventually reconnectgraft nephropathy. Consistent with this hypothesis are
the clinical correlations suggesting that an imbalance to recipient lymph vessels within 10 to 14 days [101],
unless disrupted by rejection. During acute rejection,between recipient metabolic demands and graft renal
mass explains chronic allograft nephropathy. The three- there is an increased production of lymph fluid and dis-
ruption of the lymphatic microvascular endothelial junc-year graft survival rates of transplants that come from
female, black, very young, or very old donors are less tions, which retards lymphatic flow [102, 103]. Obstruc-
tion of the lymphatics that drain the vessel wall causescompared with grafts from donors who are supposedly
endowed with a larger nephron mass [90], but the studies vessel wall lesions, as observed in chronic allograft ne-
phropathy [104]. Therefore, it is conceivable that chronicthat more directly examined the relationship of nephron
mass, recipient metabolic needs, and long-term outcome allograft nephropathy emerges from either a primary
vascular lesion, a primary tissue lesion with disruptionhave been inconsistent, in part because of difficulties in
measuring nephron mass. Although there is a consensus of the graft lymphatics and secondary vascular lesions,
or a combination thereof.that high recipient weights are associated with shortened
graft survival [91–93], it is not clear whether this results
Cytokine excess theoryfrom glomerular hyperfiltration and hypertension, inade-
quacies of immunosuppressive medication, or some Chronic allograft nephropathy can be regarded as a
process of excessive scar formation in response to injury,other as yet unidentified mechanism. It has furthermore
been argued that focal glomerulosclerosis, the histopath- resulting in the disruption of the normal tissue architec-
ture and function. It has been proposed that repetitiveological hallmark of glomerular hyperfiltration and hy-
pertension, is not a prominent feature of human chronic injury over a short period of time results in excessive
production of fibrogenic cytokines, including but not re-allograft nephropathy [94], although glomerular hyper-
filtration does seem to occur while it is unknown whether stricted to TGF-b. These cytokines promote excessive
deposition of extracellular matrix proteins with or with-these kidneys have glomerular hypertension [95, 96].
These observations, together with experimental evi- out concomitant impaired breakdown. Genotypically
high TGF-b producers seem at increased risk of losingdence [88, 89, 97, 98], strongly suggest that glomerular
hyperfiltration plays a modulating role in chronic allo- their graft late after transplantation [75, 105], and TGF-b
mRNA and protein expression are enhanced in kidneygraft nephropathy, perhaps in the subgroup of patients
with transplant glomerulopathy [40]. grafts with chronic allograft nephropathy [106, 107].
TGF-b is a multifunctional cytokine that plays a central
role in extracellular matrix production and degradation,
HYPOTHESIS TO EXPLAIN CHRONIC
and its net effect, in general, is to promote the accumula-
ALLOGRAFT NEPHROPATHY
tion of extracellular matrix. The regulation of the amount
Vascular versus interstitial injury of biologically active TGF-b is complex and is a function
of its production rate, its rate of enzymatic release fromBecause vascular rejection correlates most strongly
with graft prognosis [33], the prevailing hypothesis to a larger protein complex, the availability of a signal trans-
ducing TGF-b receptor, as well as the presence of solubleexplain chronic allograft nephropathy is that the vascular
injury initiates a sequence of events as described in the or cellular TGF-b–binding molecules [108, 109]. Kidney
transplants with chronic allograft nephropathy have en-“response to injury” hypothesis [99]. Vessel wall prolifer-
ation and vascular sclerosis result from growth-regulat- hanced expression of urokinase plasminogen activator
(uPA), its receptor, and plasminogen activator inhibitoring cytokines produced by endothelial and smooth mus-
cle cells in response to previous vessel wall injury, type 1 [110], and it is believed that uPA activates TGF-b.
We recently demonstrated that rats with chronic allo-resulting in the activation of self-amplifying autocrine
and paracrine activation cascades. If the vessel wall le- graft nephropathy produce antibodies reactive with mes-
angial cell focal adhesion plaque proteins [111] and vari-sions are the primary lesions of chronic allograft ne-
phropathy, the glomerular and tubulointerstitial lesions ous as yet only partly characterized molecules such as
biglycan and decorin. The latter compounds are smallare considered either secondary or collateral to these
vascular lesions. However, a number of clinical and ex- proteoglycan molecules produced by activated reactive
with mesangial cells that bind and inactivate TGF-bperimental observations are difficult to reconcile with
this hypothesis. Based on extensive histopathological and stimulate the release of matrix metalloproteinase
collagenases by fibroblasts [112]. It is conceivable thatstudies, Demetris et al therefore proposed their immuno-
lymphatic hypothesis [100]. According to this hypothesis, antibodies against biglycan and decorin bind to and inac-
tivate these molecules in vivo, resulting in less activechronic allograft nephropathy emerges as a result of dis-
ruption of the graft microvascular lymphatic drainage TGF-b–binding molecules, decreased production of col-
lagenases, and impaired fibrillogenesis. The role of de-secondary to foci of tissue inflammation within the graft
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corin in limiting glomerular sclerosis has been illustrated Available data thus suggest that chronic allograft ne-
phropathy may result from a diversity of processes: thein a rat model of mesangial glomerulonephritis [109]. It
is furthermore conceivable that antibodies against mes- induction and the persistence of alloimmune or autoim-
mune responses against cryptic graft antigens exposedangial cell focal adhesion plaques disrupt important sig-
naling molecules associated with focal adhesion com- to the recipient immune system in a proinflammatory
milieu, an excessive scarring response as a result of aplexes [113] and result in increased cell proliferation or
matrix formation. dysregulation of tissue repair mechanisms, apoptosis as
a result of lack of survival signals or active fraternicide,
Loss of supporting extracellular matrix architecture or the accelerated senescence of graft parenchymal cells
after multiple stresses. Whatever the ultimate mecha-The importance of disruptions of the three-dimen-
sional extracellular matrix has not received much atten- nism turns out to be, graft damage and activation seem
to play a key pathogenetic role, and measures to preventtion in considerations regarding the pathogenesis of
chronic allograft nephropathy. Anatomical structures chronic allograft nephropathy should primarily aim to
minimize tissue damage and activation at each stage insuch as blood vessels can regenerate after tissue damage,
whereas other structures such as renal tubules are depen- the life span of a transplant.
dent on an intact extracellular matrix framework that
determines and maintains the tissue organization. Tubu-
TREATMENT OPTIONS
lar epithelial cells must find an intact tubular basement
Experimental studies have shown that immune toler-membrane upon which to attach, to proliferate, and to
ance in animals prevents chronic allograft failure [122,organize their polarity; if they do not find this structure,
123], but there is no evidence yet in humans that suchthey will undergo integrin-dependent apoptosis [114] or
protocols are clinically feasible. Some of the newer im-will perhaps transdifferentiate to fibroblasts [115]. Inter-
munosuppressive drugs, especially those that also inhibitleukin-1 or tumor necrosis factor, proinflammatory cyto-
smooth muscle cell and myofibroblast proliferation,kines produced during tissue damage, can stimulate Fas
seem effective in animal models to prevent chronic allo-expression in renal tubular cells [116]. The expression
graft nephropathy when given prophylactically [124,of such a death receptor together with FasL expression in
125]. Unfortunately, there is currently no establishedneighboring tubular cells may induce a cycle of fratricidal
maintenance immunosuppressive regimen that decreasesapoptosis that results in tubular atrophy and interstitial
chronic allograft nephropathy in humans. This could, atfibrosis. However, when the tubular basement mem-
least in part, be explained by the increasing use of olderbrane is disrupted, tubular epithelial cells that have been
and marginal donors [29], and it is perhaps not expectedlost through either cytotoxic [117] or apoptotic mecha-
that more potent immunosuppression will be of any ther-nisms will not be able to regenerate and fibrosis may
apeutic benefit in such situations.ensue. The role of antibodies against basement mem-
Several nonimmunosuppressive drugs have been testedbrane antigens, as found in humans and rats with chronic
in experimental models, including eicosanoid and plate-allograft dysfunction and nephropathy, is presently un-
let-activating factor antagonists [reviewed in 126], hepa-known [118, 119].
rinoids [127], somatostatin analogues [128], insulin-like
Premature senescence theory growth factor antagonists [129], angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers [88,Recently, it has been proposed that chronic allograft
130], estrogens [131], and nitric oxide donors [132]. Anephropathy represents an exhaustion or senescence of
retrospective clinical study supports the hypothesis thatgraft endothelial or tubular cells [94, 120]. Somatic cells
angiotensin-converting enzyme inhibitors are beneficialin culture are limited in the number of cell divisions they
in chronic allograft nephropathy [133], but controlledcan undergo, a phenomenon referred to as the Hayflick
clinical trials are needed to provide proof. However,limit [121]. After this finite number of divisions, they
such studies will be difficult because of difficulties inbecome senescent and irreversibly shut down a number
trial design and entry criteria, the need to enroll largeof processes such as replication and energy generation;
numbers of patients and to follow them for long periodshistologically, senescence is characterized by atrophy.
of time, unless appropriate surrogate end points canThe multitude of stresses that act on graft cells may lead
be defined that would allow a shorter follow-up periodto their premature senescence and consequent failure to
[134, 135].exert their regulatory influence over a variety of func-
Although none of the recommendations proposed totions such as tissue repair. Inflammation and fibrosis, for
avoid chronic allograft nephropathy have been testedexample, are under control of the healing processes in
formally, it would seem prudent to recommend the fol-a healthy tissue, but senescent cells may fail to control
lowing strategies. First, avoid graft damage as a resultfibrosis. Thus, fibrosis arises according to this hypothesis
from an exhaustion of graft cells after multiple stresses. of ischemia-reperfusion injury. Although superoxide dis-
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proposal from the Fourth Alexis Carrel Conference on Chronicmutase given at the time of surgery seems effective to
Rejection and Accelerated Arteriosclerosis in Transplanted Or-
prevent chronic allograft nephropathy [136], the drug gans. Transplant Proc 25:2022–2023, 1993
does not universally prevent chronic allograft nephropa- 7. Riggio RR, Haschemeyer R, Suthanthiran M, Cheigh J, Tapia
L, Stubenbord W, Miller I, Stenzel KH: Predictability of renalthy changes [137], and the commercial availability of the
allograft failure time in long-term survivors: A hypothesis. Trans-drug is questionable. Second, acute rejection episodes plant Proc 17:2311–2313, 1985
should be treated aggressively to ensure complete rever- 8. Kasiske BL, Heim-Duthoy KL, Tortorice KL, Rao KV: The
variable nature of chronic declines in renal allograft function.sal of graft function [39]. Surveillance biopsies are per-
Transplantation 51:330–334, 1991haps useful to diagnose vascular rejections, which, if diag- 9. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL:
nosed, should be treated promptly [33]. It remains to be Chronic renal allograft rejection: Immunologic and nonimmuno-
logic risk factors. Kidney Int 49:518–524, 1996seen whether more aggressive treatment of late acute
10. Raine AEG: Does antihypertensive therapy modify chronic allo-rejection episodes will decrease the incidence of chronic graft failure? Kidney Int 48(Suppl 52):S107–S111, 1995
allograft nephropathy. The impact of antiviral therapy 11. Luo H, Nishioka T, Eigler NL, Forrester JS, Fishbein MC,
Berglund H, Siegel RJ: Coronary artery restenosis after balloonon chronic allograft nephropathy is also unknown. At
angioplasty in humans is associated with circumferential coronarythis stage, there are also no clinical data to show that
constriction. Arterioscler Thromb Vasc Biol 16:1393–1398, 1996
lipid or blood pressure lowering through medication will 12. Barrientos A, Portoles J, Herrero JA, Torralbo A, Prats D,
Gutierrez-Millet V, Blanco J: Glomerular hyperfiltration asdecrease graft loss from chronic allograft nephropathy,
a nonimmunologic mechanism of progression of chronic renalbut the lack of clinical data is no justification to ignore
rejection. Transplantation 57:753–756, 1994
post-transplant hypertension and hyperlipidemia, as they 13. Cheigh JS, Mouradian J, Soliman M, Tapia L, Riggio RR, Sten-
zel KH, Rubin AL: Focal segmental glomerulosclerosis in renalwill very likely impact patient cardiovascular morbidity
transplants. Am J Kidney Dis 2:449–455, 1983and mortality [138, 139]. Based on animal data, the use
14. Hamburger J, Crosnier J, Dormont JA: Observations in patients
of antihypertensive drugs, especially angiotensin-con- with a well tolerated homotransplanted kidney. Ann NY Acad
verting enzyme inhibitors or angiotensin receptor block- Sci 120:558–577, 1964
15. Olsen TS: Pathology of allograft rejection, in Kidney Transplanters, prolongs graft survival in chronic allograft nephropa-
Rejection: Diagnosis and Treatment, edited by Burdick JF, Racu-thy [88, 97], but careful monitoring of graft function sen LC, Solez K, Williams GM, New York, Basel, Hong Kong,
and electrolytes is necessary. Strategies to treat post- Marcel Dekker, 1992, p 333
16. Habib R, Antigua C, Hinglais N, Gagnadoux MF, Broyer M:transplant hyperlipidemia have recently been reviewed
Glomerular lesions in the transplanted kidney in children. Am J[140, 141]. With the current financial pressures on health
Kidney Dis 10:198–207, 1987
care systems, there is a tendency to transfer long-term 17. Monga G, Mazzucco G, Messina M, Motta M, Quaranta S,
Novara R: Intertubular capillary changes in kidney allografts: Afollow-up of renal transplant patients to peripheral
morphologic investigation on 61 renal specimens. Mod Patholhealth care physicians, but careful long-term follow-up
5:125–130, 1992
with appropriate counseling on medication and monitor- 18. Ivanyi B, Fahmy H, Szenohradszky P, Hansen H, Olsen S,
Halloran P, Solez K: Peritubular capillary basement membraneing of drug adherence should remain a high priority
changes in chronic renal allograft rejection. Transplant Proc (in[142].
press)
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